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Inﬂammation is one of the predisposing factors known to be associated with Epstein Barr Virus (EBV)
mediated tumorigenesis. However it is not well understood whether inﬂammation in itself plays a role
in regulating the life cycle of this infectious agent. COX-2, a key mediator of the inﬂammatory processes
is frequently over-expressed in EBV positive cancer cells. In various tumors, PGE2 is the principle COX-2
regulated downstream product which exerts its effects on cellular processes through the EP1-4
receptors. In this study, we further elucidated how upregulated COX-2 levels can modulate the events
in EBV life cycle related to latency-lytic reactivation. Our data suggest a role for upregulated COX-2 on
modulation of EBV latency through its downstream effector PGE2. This study demonstrates a role for
increased COX-2 levels in modulation of EBV latency. This is important for understanding the
pathogenesis of EBV-associated cancers in people with chronic inﬂammatory conditions.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Epstein Barr Virus (EBV) is a gamma herpesvirus ubiquitous in
humans, and is widely known for its oncogenic properties. After
primary infection, EBV follows two distinct life cycles in humans, a
lytic form of infection with production of virion particles, or long-
term latency. The switch between the latent and the lytic life cycle
of EBV is the result of highly regulated interaction of EBV with its
host and can be divided into three stages: (i) EBV infects human B
lymphocytes resulting in proliferation of the infected cells, (ii) it
can enter its latent phase with stringent expression of its latent
genes as the cell proliferate, and (iii) it can be reactivated resulting
in the release of infectious viral progeny for infection of new cells
or transmission of the virus to other individuals. Lytic infection
leads to extensive viral gene expression, production of new
infectious virions and ﬁnally death of the infected host cell
(Chang et al., 2012). A latent form of infection allows the virus to
persist in a dormant form for the life of the host through its tightly
restricted gene expression (Woellmer et al., 2012). The latently
infected cells can also undergo lytic reactivation in response to
certain stimuli. Importantly, EBV lytic reactivation is linked to
development and progression of EBV associated malignancies
including nasopharyngeal carcinoma and lymphoma (Liu et al.,
2012). Interestingly, triggering EBV lytic reactivation has also
generated much attention as a potential therapeutic strategy as
expression of lytic antigens in EBV positive tumor cells will induce
strong immune response to the viral lytic proteins, thus killing
tumour cells (Giunco et al., 2013).
One of the predisposing factors known to be associated with
EBV mediated tumorigenesis is inﬂammation. A connection bet-
ween inﬂammation and cancer has been long suspected
(Sgambato and Cittadini, 2010). Epidemiological studies have
established that many tumors occur in association with chronic
infections (Ziegler and Buonaguro, 2009). However it is not well
understood whether inﬂammation in itself plays a role in regulat-
ing the life cycle of infectious agents. This is important speciﬁcally
for infections like EBV whose life cycle involves long periods of
latency during which the virus is immunologically undetectable
and remains dormant. Inﬂammatory response against virus infec-
tion has been linked to virus pathogenesis leading to tumorigen-
esis, which includes cellular transformation, promotion, survival,
proliferation, invasion, angiogenesis, and metastasis (Chen et al.,
2013; Taniguchi et al., 2013). Thus, it is essential to identify the
changes in the life cycle of the virus due to inﬂammation and their
signiﬁcance for driving the oncogenic process.
COX-2, a key mediator of the inﬂammatory processes, is
frequently expressed in EBV positive nasopharyngeal tumors as
well as detected at higher levels in EBV positive Lymphoblastoid
cell lines when compared to EBV negative nasopharyngeal tumors
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or EBV negative Burkitt's lymphoma cell lines. These observations
suggest a role for COX-2 in EBV pathogenesis. Cyclooxygenase
(COX) is a key enzyme in the biosynthetic pathway of prostaglan-
din (PG) synthesis. COX-1 and COX-2 are the two isoforms of COX
(O’Neill and Ford-Hutchinson, 1993). COX-1 is constitutively
expressed while COX-2 is an inducible early response gene
(Satoh et al., 2012). Over-expression of COX-2 catalyzes the
synthesis of PGE2 whose downstream target molecules contribute
to physiological processes including transformation, survival, pro-
liferation, metastasis and angiogenesis by up-regulating several
signaling pathways and down-regulating apoptotic proteins (Satoh
et al., 2012). COX-2 and PGE2 have been reported to have a positive
correlation with various types of cancers including colon cancer,
lung cancer, and gastric cancer (Nadda et al., 2012; Shin et al.,
2012). The depth of invasion and carcinoma development has been
shown to parallel the increase in expression of COX-2 (Coussens
and Werb, 2002; Fujita et al., 2002). COX-2 can be induced by
several intracellular and extracellular factors including lipopoly-
saccharide (LPS), epidermal growth factor (EGF), and tumor
necrosis factor (Font-Nieves et al., 2012; Medeiros et al., 2010;
Yucel-Lindberg et al., 1999). Published studies have revealed a
close association between COX-2 over-expression and EBV asso-
ciated cancers (Michelow et al., 2012; Murray and Young, 2001). A
convincing positive correlation has been reported between COX-2
and the EBV viral protein LMP1. LMP1 can up-regulate COX-2
which accelerates lymph node metastasis in NPC (Bai and Tang,
2009). We have earlier shown that the EBV latent antigen EBNA3C,
can upregulate COX-2 in association with the metastasis suppres-
sor Nm23-H1 (Kaul et al., 2006).
In various tumors, PGE2 is the principle COX-2 regulated
downstream product. PGE2 exerts its cellular effect through the
EP1-4 receptors (Konger et al., 2005). The EP receptors belong to a
family of G-protein coupled receptors (Narumiya et al., 1999; Tober
et al., 2006). Despite close resemblance among all EP receptors,
they exhibit differential binding afﬁnities for PGE2 molecule and
all four receptors are associated with different intracellular signal-
ing cascades. Recently, the explicit roles of each EP receptors in
tumorigenesis and malignancies have begun to draw tremendous
attention. The EP1 receptor is speciﬁcally known to be associated
with distinct signaling cascades, as compared to the other three EP
receptors and behaves differently in cancer progression (Ma et al.,
2013b). EP1 is also closely related to inﬂammation, skin cancer,
colon carcinogenesis and late stage breast cancer progression. EP1
receptor induces elevation and mobilization of intracellular Caþ2
(Irie et al., 1994; Sugimoto and Narumiya, 2007). EP4 is a 65 KDa
protein which is coupled with phosphatidylinositol kinase and
elevated cAMP level (Hull et al., 2004; Luschnig-Schratl et al.,
2011). It is associated with various human cancer and its elevated
mRNA level has been detected in breast cancer (Xia and Kirkman,
1990), colorectal cancer (Chell et al., 2006), and Prostate cancer
(Biedrzycka et al., 2013). EP4 antagonists are also used for treat-
ment of various immune diseases (Yao et al., 2009). It is used as an
anti-inﬂammatory agent against diseases associated with inﬂam-
mation (Luschnig-Schratl et al., 2011).
In nature, the biological processes associated with inﬂamma-
tion are required to extend defense to host against microbial
infection by mediating cell growth, tissue repair and regeneration.
Several metabolites secreted by infectious agents are responsible
for inﬂammation thereby facilitating transformation and progres-
sion towards cancer (Antonic et al., 2013). Still, it is very difﬁcult to
predict how inﬂammation and associated pathways can modulate
the life cycle of infectious agents. This is especially true for
infections associated with viruses like EBV closely related to
several human cancers. The life cycle of EBV is divided into latent
and lytic phases, and the latent genes expressed during the latent
cycle of the virus cleverly escape the immune system and remain
virtually undetectable. However a number of conditions can
induce the virus to undergo lytic reactivation. This transition from
latent to lytic phase has not been completely explored. The lytic
phase involves production of infectious viral particles which are
important for infecting new host as well as new cells in same host.
In this study, we further strive to understand the events related to
inﬂammation characterized by upregulated COX-2 levels to mod-
ulate events in the EBV life cycle related to lytic reactivation. This
adds to our understanding of how these host-viral interactions
modulate the microenvironment contributing to transformation
and cancer.
Results
LPS induces COX-2 expression in EBV positive lymphoblastoid cells
To investigate the role of inﬂammation on EBV latency we used
puriﬁed LPS as an extracellular inducer to modulate COX-2 up-
regulation in EBV latently infected cells. LPS is a biologically active
compound found in the outer membrane of gram negative bacteria
(Noguchi et al., 2001). In our study, we found that the addition of
LPS correlated with COX-2 over-expression at the protein level in
two EBV positive cell lines (LCL2, B95-8) resulting in approxi-
mately 2 to 4 fold increase (Fig. 1A and B) (po0.001). GAPDH was
used as an internal control for normalization. The experiments
were performed three times independently and the data pre-
sented as the mean with standard error. The COX-2 overexpression
was not as high as seen in cell of epithelial origin such as HeLa
(410 fold) (data not shown). We had earlier shown that LPS does
not result in COX-2 upregulation in EBV negative Burkitt's lym-
phoma cells, whereas it is signiﬁcantly upregulated in latently
infected EBV-positive cells (Kaul et al., 2006). These results
indicate that LPS induces EBV positive lymphoid cells resulting
in enhanced COX-2 expression in the absence of an overwhelming
pro-inﬂammatory response as seen in other cell types. This may be
either because the LPS receptor TLR4 is expressed in only a small
percentage of EBV infected cells (Komai-Koma et al., 2004), or by
some alternate mechanism.
COX-2 over-expression results in lytic reactivation of EBV in latently
infected cells
To study the effect of COX-2 up-regulation on EBV latency, we
treated the EBV latently infected LCL2, B95-8 and Burkitt's lym-
phoma Akata cells with LPS. We tested different concentrations of
LPS for different time points and the optimum concentration of
LPS required for detectable reactivation of EBV from B95-8 and
LCL2 cell lines was found to be 1 μg/ml. Detection of EBV in the cell
culture supernatant of induced cells peaked at 6 days post-
induction based on EBV genome copies as determined by the real
time PCR targeting BamW fragment of EBV. Signiﬁcantly higher
amounts of EBV genome were detected from supernatant of
induced cells as compared to uninduced cells (Fig. 1C) (po0.01).
The EBV genome was undetectable from supernatant of uninduced
Akata cells. Whereas when the supernatant of induced Akata cells
were tested, the level of EBV genome detected were comparable to
that detected from Nab/TPA induced Akata cells (Fig. 1G). To
conﬁrm the role of COX-2 in EBV lytic reactivation we used COX-
2 speciﬁc inhibitor NS-398 (Copeland et al., 1994). NS-398 has
been reported to act through direct interaction with COX-2. This
results in structural transition of the enzyme leading to a very
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tight association with the inhibitor (Copeland et al., 1994). EBV
latently infected LCL2 and B95-8 cells were treated with LPS and
incubated for 6 days in the presence or absence of the COX-2
speciﬁc inhibitor NS-398. The supernatant was harvested after six
days and tested for the presence of EBV by real time PCR targeting
the BamW region of EBV (see materials and methods). Addition of
Fig. 1. LPS mediated COX-2 upregulation is coincident with EBV lytic reactivation, gp350 and PGE2 expression, and is inhibited by the COX-2 inhibitor NS-398: The addition
of LPS correlated with COX-2 over-expression at the protein level in two EBV positive cell lines (LCL2, B95-8) resulting in approximately 2 to 4 fold increase (A, B) (po0.001).
Signiﬁcantly higher amounts of EBV genome were detected from supernatant of induced cells as compared to uninduced cells (C) (po0.01). The EBV late lytic protein gp350
protein was detected at a signiﬁcantly higher levels (po0.001) as compared to uninduced cells (D). Addition of NS-398 resulted in a signiﬁcant reduction of 2.6 to 3 fold
(po0.01) in the amount of EBV copies detected in cell culture supernatant (E). The mean PGE2 concentration in the supernatant of LPS treated EBV latently infected LCL2 was
254 pg/ml as compared to un-induced LCL2 at 187 pg/ml indicating a 35% increase (po0.001) in PGE2 levels (F). In case of HeLa cells there was an approximately 4-fold
increase (from 265 pg/ml to 1027 pg/ml) (po0.001) in PGE2 levels. The overall increase in PGE2 levels in treated 293T cells was not so robust (from 214 pg/ml to 275 pg/ml)
(po0.01).The induction of Burkitt lymphoma Akata cells by LPS resulted in detection of EBV genome from supernatant of induced cells, at levels comparable to that in
supernatant of NaB/TPA induced Akata cells (G). Addition of NS-398 resulted in a signiﬁcant reduction of about 7 fold (po0.01) in the amount of EBV copies detected in cell
culture supernatant (E).
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NS-398 resulted in a signiﬁcant reduction of 2.6 to 3 fold (po0.01)
in the amount of EBV copies detected in cell culture supernatant
(Fig. 1E) indicating that-LPS mediated lytic reactivation of EBV
occurs predominantly through COX-2 regulated pathways and its
downstream effector molecules. Similar results were observed
when experiments were performed using Burkitt's lymphoma
Akata cells resulting in up to 7 fold reduction (po0.01) in amount
of EBV genome detected from cell culture supernatant, when NS-
398 was added along with LPS (Fig. 1G). The lytic reactivation of
EBV in latently infected cells is accompanied by an increased
expression of the EBV late lytic protein gp350 (Gong and Kieff,
1990). When LPS treated EBV latently infected LCL2 were tested for
gp350 expression levels, the gp350 protein was detected at a
signiﬁcantly higher levels (po0.001) as compared to uninduced
cells (Fig. 1D).
The COX-2 downstream effector prostaglandin E2 (PGE2) and
prostanoid receptors EP1 and EP4 are induced during COX-2
mediated EBV lytic reactivation
An increase in COX-2 levels in response to various inﬂamma-
tory stimuli simultaneously leads to a dramatic increase in
production of pro-inﬂammatory molecule PGE2 (Satoh et al.,
2012). Among these, the PGE2 is a crucial COX-2 mediated
metabolic product of arachidonic-acid (Satoh et al., 2012). It is
also a key molecule involved in inﬂammation and exerts its action
through the membrane receptors EP1-4 located on the surface of
target cells (Konger et al., 2005). These receptors belong to a
family of G- protein coupled receptors (GPCR) (Ahmad et al., 2013;
Ma et al., 2013a; Narumiya et al., 1999; O’Banion et al., 1991;
O’Callaghan et al., 2013). To understand the role of these COX-2
downstream effector molecules, we determined if there was any
modulation of their expression patterns which occurred simulta-
neously to EBV lytic reactivation. The results showed that 24 h
post-induction, the level of PGE2 in the supernatant collected from
the induced cells, was signiﬁcantly higher (po0.001) as compared
to the un-induced control samples (Fig. 1F). This correlated with
the amount of virus detected in the supernatant of treated cells.
The mean PGE2 concentration in the supernatant of LPS treated
EBV latently infected LCL2 was 254 pg/ml as compared to un-
induced LCL2 at 187 pg/ml indicating a 35% increase (po0.001) in
PGE2 levels (Fig. 1F). Similar results were observed for EBV
negative HeLa and 293T cells. In case of HeLa cells there was an
approximately 4-fold increase (from 265 pg/ml to 1027 pg/ml)
(po0.001) in PGE2 levels. Interestingly, overall increase in PGE2
levels in treated 293T cells was not so robust (from 214 pg/ml to
275 pg/ml) (po0.01). This is most likely due to the low expression
levels of TLR4 receptors on 293T cells which are critical for LPS
signaling pathway (Medvedev and Vogel, 2003). Therefore LPS-
mediated COX-2 upregulation and modulation of COX-2 down-
stream effector molecules can occur irrespective of EBV infection
status of the cell. Interestingly, such upregulation is more sig-
niﬁcant in cells of epithelial origin as compared to EBV infected
lymphoid cells.
We examined whether or not, there was any difference in the
expression of EP receptors which was concurrent with EBV lytic
reactivation as a result of COX-2 upregulation. The expression
levels of EP receptors transcripts in EBV positive cell lines (LCL2,
B95-8) was analyzed in cells after treatment with LPS. The cells
were assayed using real time RT-PCR to determine the relative
changes in mRNA transcript level of the EP receptors. The results
showed that both EP1 and EP4 transcripts were signiﬁcantly up-
regulated in response to COX-2 upregulation by LPS (Fig. 2A and
B). The EP1 mRNA transcripts showed a 5.4-fold upregulation
(po0.001) as compared to uninduced cells when tested in LCL2
(Fig. 2A, compare lanes 3 and 4). Whereas, EP4 transcripts were
increased greater than 40 fold (po0.001) compared to uninduced
LCL2 (Fig. 2B, compare lanes 3 and 4). Interestingly, the EBV
negative BJAB cells did not show any signiﬁcant changes in the
transcripts levels of the EP1 or EP4 receptors even when treated
with LPS. Importantly, the transcript levels of the EP2 and EP3
receptors did not show any signiﬁcant changes (data not shown)
when LCL2 were treated with LPS when compared to uninduced
cells and BJAB. To determine whether changes in EP1 and EP4
transcript levels correlated to a corresponding increase in protein
expression levels, we treated LCL2 with LPS and assayed the EP1
and EP4 levels by western blotting using EP1 and EP4 speciﬁc
antibodies, respectively. The expression levels of the receptors
were normalized using GAPDH as a loading control. We found
elevated expression of EP1 up to 4-fold (Fig. 2C) (po0.05) and EP4
up to 2.5-fold (Fig. 2D) (po0.05) in EBV positive cells (LCL2) in
response to LPS treatment. This was coincident with EBV lytic
reactivation, as compared to the uninduced control samples.
Similar up regulation was observed in EBV negative HeLa cells as
well (Fig. 2E and F) (po0.05).
Immunoﬂuorescence studies on EBV latently infected cells also
showed that LPS induction of these cells resulted in lytic reactiva-
tion of EBV and is accompanied with elevated COX-2, EP1 and EP4
expression (Fig. 3). We used LCL2 (human B-cell) as well as B95-8
(marmoset B cells) for these studies. The COX-2 immunoﬂuores-
cence signals in induced cells were much stronger as compared to
uninduced cells, and were localized both in the cytoplasm and
nucleus (Fig. 3A and B, top panel). COX-2 has been previously
reported to be localized in nucleus and function as transcriptional
factor (78). EP1 and EP4 signals were also much stronger in LPS
treated LCL2 and B95-8 (Fig. 3A and B, middle panels). Both EP1
and EP4 were predominantly localized in the cytoplasm and
mainly on the cell membrane (Fig. 3A and B, middle panels). Thus,
our data clearly showed that induction with LPS resulted not only
in enhanced expression of COX-2, but was also concurrent with
increased extra-cellular PGE2 levels along with increased expres-
sion of the prostaglandin speciﬁc downstream effectors EP1 and
EP4 at the mRNA and protein expression levels. The induced cells
also showed signiﬁcantly (up to 20-fold) (po0.001) increased
expression of EBV late lytic protein gp350 (Fig. 3A and B, bottom
panel). These data strongly suggest a direct role of EP1 and EP4
receptors in COX-2 mediated lytic reactivation of EBV.
A fraction of cells with enhanced EP1 or EP4 expression undergo lytic
reactivation
To understand the role of EP1 and EP4 over expression in
induction of EBV lytic reactivation in latently infected cells, we
examined what percentage of EP1 or EP4 over expressing cells co-
expressed with EBV late lytic protein gp350. Our data showed that
EP1 or EP4 signals were detected in approximately 23–25% of
uninduced B95-8 cells as compared to 70–85% in induced cells
(po0.01) (Fig. 4A and B). The gp350 expression was undetectable
in uninduced B95-8 cells, whereas approximately 29% of EP1
expressing and 23% of EP4 expressing B95-8 cells were also
positive for gp350 (Fig. 4A and B) (po0.01). Similar results were
observed when experiment was repeated in LCL2 cells. The EP1 or
EP4 signals were detected in approximately 11–28% of uniduced
LCL2 cells as compared to 64–65% in induced cells (po0.01)
(Fig. 4C and D). The gp350 expression was undetectable in
uninduced LCL2 cells, whereas approximately 46% of EP1 expres-
sing and 54% of EP4 expressing LCL2 cells were also positive for
gp350 (Fig. 4C and D) (po0.01).
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COX-2 mediated EBV reactivation Is restricted in the presence of EP1
and EP4 speciﬁc inhibitors
To validate the role of EP1 and EP4 receptors in COX-2 mediated
lytic reactivation of EBV, we then used speciﬁc inhibitors against
the EP receptors. The speciﬁc inhibitor AH6809 was used for
blocking EP1 receptor (Zhao et al., 2011). AH6809 (6-isopropoxy-
9-oxoxanthene-2-carboxylic acid) is a known EP1 antagonist and
is also reported to work against EP2 and DP receptors (Zhao et al.,
2011). We used AH23848 to inhibit the EP4 receptor (Vo et al.,
2013). EBV latently infected LCL2 cells were treated with LPS and
incubated with or without EP1 and EP4 speciﬁc inhibitors at non-
cytotoxic doses described in material and method section. The EP
inhibitors were either added 3 days prior to LPS treatment, or
simultaneous to LPS treatment, or 3 days post LPS treatment. The
cell culture supernatant was harvested six days after LPS
treatment and tested for the presence of EBV by real time PCR
using Bam W primers as described in material and methods
section. For the EP1 receptor, the addition of the inhibitor 3 days
prior to LCL2 induction resulted in a 14-fold reduction (po0.001)
in virus detection as compared to no inhibitor control (Fig. 5A,
compare lanes 1 and 4). The addition of the EP1 inhibitor
simultaneously to LPS induction of LCL2 also reduced the virus
detection by 1.35 fold (Fig. 5A, compare lanes 1 and 3) (po0.05).
For EP4 receptor, the addition of the inhibitor 3 days prior to LCL2
induction resulted in a 10-fold reduction (po0.001) in virus
detection as compared to no inhibitor control (Fig. 5B compare
lanes 1 and 4). The addition of EP4 inhibitor simultaneously with
LPS treatment of LCL2 did not block virus lytic reactivation (Fig. 5B,
compare lanes 1 and 3).
These experiments above were repeated in B95-8 cells, and a
similar pattern was observed (Fig. 5C and D), although the degree
Fig. 2. LPS mediated COX-2 upregulation results in upregulation of the EP1 and EP4 receptors: Both EP1 and EP4 receptors were transcriptionally upregulated in LCL2 but not
in EBV negative BJAB cells in response to LPS induction (panel A and B). The EP1 mRNA transcripts showed a 5.4-fold upregulation (po0.001) as compared to uninduced cells
when tested in LCL2 (A, compare lanes 3 and 4). Whereas, EP4 transcripts were increased greater than 40 fold (po0.001) compared to uninduced LCL2 (B, compare lanes
3 and 4). LPS mediated COX-2 upregulation of EBV latently infected cells as well as EBV negative cancer cells of epithelial origin results in over-expression of EP1 and EP4
receptors. The expression of EP1 was elevated up to 4-fold (C) (po0.05) and EP4 up to 2.5-fold (D) (po0.05) in EBV positive cells (LCL2) in response to LPS treatment. This
was coincident with EBV lytic reactivation, as compared to the uninduced control samples. Similar up regulation was observed in EBV negative HeLa cells as well (E and F)
(po0.05).
J. Gandhi et al. / Virology 484 (2015) 1–14 5
of inhibition of lytic reactivation (1.2 to 1.5 fold) (po0.05) was not
as dramatic as seen in LCL2 indicating some redundancy in
downstream pathways in these cells. Moreover, when the inhibi-
tors against the EP1 and EP4 receptors were added together prior
to LPS treatment, a complete inhibition of EBV reactivation was
observed (Fig. 5E, compare lanes 1 and 4) (po0.001). It is also
important to mention that addition of inhibitors at any time
simultaneous or post LPS induction did not result in any signiﬁcant
inhibition of EBV reactivation (Fig. 5A–E, compare lanes 3 and 4).
Our results clearly indicated a role for the EP1 and EP4 receptors in
COX-2 mediated lytic reactivation of EBV.
Co-cultivation of COX-2 expressing cells with EBV latently infected
cells can induce EBV lytic reactivation
The COX-2 downstream effector molecule PGE2 is known to act
on target cells in autocrine as well as paracrine mode (Dohadwala
et al., 2002). PGE2 is a critical molecule in amplifying and generating
a self-perpetuating cycle that induces inﬂammation and cancer
(Dagouassat et al., 2013). It has been previously reported that
patients suffering from chronic inﬂammatory conditions like rheu-
matoid arthritis have a high incidences of EBV associated malig-
nancies (Dagouassat et al., 2013; Kondo et al., 2013; Lossius et al.,
2013). Our data in this manuscript have shown that PGE2 released
in response to COX-2 upregulation in EBV latently infected cells can
result in lytic reactivation most likely through an autocrine mode of
action. We have also shown that LPS induction of EBV negative cells
such as 293T and HeLa can also upregulate COX-2, EP1, EP4
expression and PGE2 release from these cells. We hypothesize that
a chronic inﬂammatory condition characterized by increased
COX-2 expression in inﬂamed cells can induce lytic reactivation of
EBV in latently infected cells even at far off sites in vivo through
paracrine activities of extracellular secreted PGE2 functioning as the
effector molecule. To determine if COX-2 upregulation can act in
paracrine mode and cause EBV lytic reactivation, we treated 10
million adherent 293T cells to increase COX-2 expression and co-
cultivated these cells or their culture supernatant, with an equal
number of latently infected EBV-positive cells. The upregulated
PGE2 levels in the supernatant of LPS treated 293T were closer to
upregulated levels observed in the supernatant of LPS treated
Fig. 3. LPS induction of EBV positive cells results in overexpression and intracellular accumulation of COX-2 as well as its downstream target receptors EP1 and EP4. Panel
(A) LCL2 were induced with LPS (1 μg/ml) for 24 h and harvested for immunoﬂuorescence assays using anti-COX-2, anti-EP1, anti EP4, and anti-gp350 antibodies. COX-2, EP1,
EP4 and gp350 expression were signiﬁcantly upregulated (po0.001) in induced cells as compared to un-induced cells. The images were analysed using Image J software for
quantiﬁcation of immunoﬂuorescence signals in at least 3 different microscopic ﬁelds for each. The mean values and standard error of three independent experiments are
presented as bar graph in right panel. Panel (B) B95-8 cells were induced with LPS (1 μg/ml) for 24 h and then processed for immunoﬂuorescence assays as described
for LCLs.
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latently infected EBV-positive cells. Therefore we determined if it
resulted in lytic reactivation of EBV. Our results clearly showed that
up-regulation of COX-2 level in 293T cells could induce lytic
reactivation of EBV in co-cultivated LCL2 cells (Fig. 6A, Lane 2)
(po0.001). The lytic reactivation observed in LCL2 co-cultivated
with induced 293T cells was comparable to that in LPS induced LCL2
(Fig. 6A, compare lanes 2 and 8). Similar results were obtained
when COX-2 overexpressing 293T cells (transfected with a COX-2
expression plasmid) were co-cultivated with LCL2 (Fig. 6A, lane 4)
(po0.05). When only the supernatant from COX-2 expressing 293T
cells was added to LCL2, this also resulted in lytic reactivation of EBV
(Fig. 6A, lane 6) (po0.001). These data clearly indicate that soluble
factors released from COX-2 expressing cells in the culture supernatant
were enough to induce lytic reactivation of EBV in latently infected
cells. To establish the speciﬁc role of PGE2, we tested the effect of
addition of exogenous puriﬁed PGE2 (Cayman Chemicals, Ann Arbor,
MI, Cat no. 414014) on latently infected EBV-positive cells. The addition
of increasing amounts of exogenous puriﬁed PGE2 at levels within
Fig. 4. A fraction of cells with enhanced EP1 or EP4 expression undergo lytic reactivation. EP1 or EP4 signals were detected in approximately 23–25% of uninduced B95-8
cells as compared to 70–85% in induced cells (po0.01) (A, B). The gp350 expression was undetectable in uninduced B95-8 cells, whereas approximately 29% of EP1
expressing and 23% of EP4 expressing B95-8 cells were also positive for gp350 (A, B) (po0.01). Similar results were observed when experiment was repeated in LCL2 cells.
The EP1 or EP4 signals were detected in approximately 11–28% of uniduced LCL2 cells as compared to 64–65% in induced cells (po0.01) (C, D). The gp350 expression was
undetectable in uninduced LCL2 cells, whereas approximately 46% of EP1 expressing and 54% of EP4 expressing LCL2 cells were also positive for gp350 (C, D) (po0.01). The
mean values and standard error of three independent experiments are presented as bar graph in right panel.
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biological range from 250 to 1000 pg/ml resulted in increased lytic
reactivation in EBV latently infected B95-8 cells (Fig. 6B). The amount of
virus detected in cell culture supernatant of PGE2 treated cells was
equivalent to the virus detected in supernatant of LPS treated cells
(Fig. 6B, compare lane 1, 2, 3 with 5). A similar pattern was observed
when LCL2 was treated with exogenous PGE2 (Fig. 6C). Our data clearly
indicated that latently infected EBV-positive cells can initiate lytic
reactivation in response to COX-2 up regulation in neighboring cells
in a paracrine mode of action. This ﬁnding may be very signiﬁcant in
addressing clinical conditions associated with chronic inﬂammation.
These observations are useful in explaining the higher incidence of EBV
associated cancers in people suffering from chronic inﬂammatory
conditions characterized by elevated COX-2 levels (Kondo et al., 2013;
Lossius et al., 2013).
EBV progeny virions produced as a result of COX-2-mediated lytic
reactivation are biologically active
To investigate the biological activity of EBV progeny generated
in response to COX-2 up regulation, freshly isolated peripheral
blood mononuclear cell (PBMC) were treated with the virus
obtained from cell culture supernatant of LPS induced EBV infected
cells. To investigate if the virus was biologically functional, ten
million PBMCs were infected with the virus. The PBMCs were
monitored daily by brightﬁeld microscopy. The results of the
infection showed that the EBV progeny virus had successfully
infected the primary B cells which are transformed leading to
immortalization and generation of Lymphoblastoid cell lines. All
cells in the uninfected control and those exposed to supernatant
Fig. 5. EBV lytic reactivation in response to LPS mediated COX-2 upregulation in latently infected cells was blocked in the presence of speciﬁc chemical inhibitors of EP1 and
EP4. Ten million EBV latently infected LCL2 (panel A) or B95-8 (panel C) were induced with LPS (1 μg/ml) and treated with EP1 speciﬁc inhibitor AH6809 either simultaneous
with LPS induction (panel A and C, lane 3) or 3 days before LPS induction (panel A, C, lane 4). Similarly the effect of EP4 inhibitor (AH23848) was tested on LPS mediated EBV
lytic reactivation in LCL2 (panel B) and B95-8 cells (panel D). The effect of simultaneous addition of EP1 and EP4 inhibitors on LPS treatment mediated EBV lytic reactivation
was tested in B95-8 cells (panel E). For the EP1 receptor, the addition of the inhibitor 3 days prior to LCL2 induction resulted in a 14-fold reduction (po0.001) in virus
detection as compared to no inhibitor control (A, compare lanes 1 and 4). The addition of the EP1 inhibitor simultaneously to LPS induction of LCL2 also reduced the virus
detection by 1.35 fold (A, compare lanes 1 and 3) (po0.05). For EP4 receptor, the addition of the inhibitor 3 days prior to LCL2 induction resulted in a 10-fold reduction
(po0.001) in virus detection as compared to no inhibitor control (B compare lanes 1 and 4). The addition of EP4 inhibitor simultaneously with LPS treatment of LCL2 did not
block virus lytic reactivation (B, compare lanes 1 and 3). These experiments above were repeated in B95-8 cells, and a similar pattern was observed (C, D), although the
degree of inhibition of lytic reactivation (1.2 to 1.5 fold) (po0.05) was not as dramatic as seen in LCL2. When the inhibitors against the EP1 and EP4 receptors were added
together prior to LPS treatment, a complete inhibition of EBV reactivation was observed (E, compare lanes 1 and 4) (po0.001).
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from uninduced B95-8 control died, but the primary B-cells
infected with EBV generated lymphoblasts which were similar to
those seen in LCLs conﬁrming the ability of EBV infectious virions
to infect and immortalize the naïve B cells (Fig. 7).
Discussion and conclusion
A number of studies have shown that the inﬂammatory
response against virus infection is linked to virus associated
pathogenesis which leads to cellular transformation, promotion,
survival, proliferation, invasion, angiogenesis, and metastasis
(Woller and Kuhnel, 2013). However, the direct role of inﬂamma-
tion in modulating life cycle events of infectious viral agents is yet
to be understood. In the case of virus like EBV whose life cycle
involves long periods of latency and subsequent reactivation, the
signiﬁcance of the inﬂammatory response needs to be carefully
evaluated. This is especially important as lytic reactivation is a
critical step in EBV life cycle and is very important for virus
dissemination to new hosts and infection of nascent cells. Reacti-
vation provides new opportunities for the virus to not only spread
to other host but also to infect naïve cells in infected host, which in
immuno-compromised patients may result in transformation and
tumorigenesis. Previous studies have demonstrated that up reg-
ulation of the modulator of inﬂammation COX-2 and its down-
stream effector molecules has a key role in EBV (Kaul et al., 2006;
Murono et al., 2001), as well as KSHV life cycle events (Paul et al.,
2013; Paul et al., 2011).
In the present study, we investigated a link between chronic
inﬂammation characterized by upregulated COX-2 levels and
induction of EBV lytic reactivation. We used LPS mediated up
regulation of COX-2 in latently infected EBV cells as a model
system. Our studies now showed that LPS addition to latently
infected EBV positive cells resulted not only in up regulation of
COX-2 but also an increased expression of its downstream effector
PGE2. The elevated COX-2 and PGE2 levels were coincident with
expression of EBV late lytic protein gp350 and detection of EBV in
cell culture supernatant indicating lytic reactivation at least in a
sub-population of infected cells. The addition of a COX-2 speciﬁc
inhibitor NS-398 resulted in a dramatic reduction in the amount of
virus detected in the cell culture supernatant indicating that LPS
mediated EBV lytic reactivation is mainly because of upregulated
COX-2 levels. Burkitt's lymphoma Akata cells also showed a similar
pattern indicating the phenomenon is likely to have biological
relevance in vivo. The increased expression of EBV lytic protein
gp350 from LPS treated cells indicate that EBV genome detected in
cell culture supernatant is from progeny virions released from cells
as a result of lytic reactivation. This along with DNaseI treatment
of supernatant before virus concentration and viral genome
extraction clearly indicate that the detected EBV sequence is not
from episomal DNA released due to cell lysis. The overexpression
of COX-2 and PGE2 in infected cells was also coincident with
overexpression of PGE2 receptors EP1 and EP4. The signiﬁcant
biological functions governed by COX-2/PGE2/EP receptors pro-
inﬂammatory axis is described in several viral-linked tumors
especially in cancer related with the family of oncogenic human
herpes virus (Paul et al., 2013). The G-protein coupled receptors
(EP1-4) govern several biochemical changes and administer pro-
cesses involving the immune system (De Keijzer et al., 2013). Our
data show that signiﬁcant overexpression of EP1 and EP4 was
detected not only at transcriptional levels but also at the protein
levels. The expression levels of both receptors were increased
several fold in treated cell lines compared to the untreated cells.
Also, the expression proﬁle of the EP4 receptor was signiﬁcant
with a dramatic rise in EP4 expression. This supports the hypoth-
esis that among all four EP receptors, EP4 may prove to be the
most versatile and important receptor. EP4 is widely known for its
cancer promoting and pro-angiogenic activities (Konya et al.,
2013). It is important to note that these receptors did not get
upregulated in response to LPS treatment in EBV negative Burkitt's
Lymphoma cells. Moreover the functional inhibition of EP1 and
EP4 receptors using chemical inhibitors dramatically reduced
COX-2 mediated lytic reactivation of EBV even when COX-2 levels
were upregulated. In fact the combined usage of inhibitors against
EP1 and EP4 completely blocked the lytic reactivation suggesting
that the majority of COX-2 mediated regulation of EBV latency is
via the EP1 and EP4 receptors. The observation that the effective
blockage of lytic reactivation required addition of EP inhibitors
prior to LPS, and did not work as efﬁciently when the inhibitors
were added simultaneously or after LPS induction, suggests that
Fig. 6. EBV latently infected cells undergo lytic reactivation when co-cultivated
with COX-2 expressing cells. The up-regulation of COX-2 level in 293T cells could
induce lytic reactivation of EBV in co-cultivated LCL2 cells (A, Lane 2) (po0.001).
The lytic reactivation observed in LCL2 co-cultivated with induced 293T cells was
comparable to that in LPS induced LCL2 (A, compare lanes 2 and 8). Similar results
were obtained when COX-2 overexpressing 293T cells (transfected with a COX-2
expression plasmid) were co-cultivated with LCL2 (A, lane 4) (po0.05). When only
the supernatant from COX-2 expressing 293T cells was added to LCL2, this also
resulted in lytic reactivation of EBV (A, lane 6) (po0.001). The addition of
increasing amounts of exogenous puriﬁed PGE2 at levels within biological range
from 250 to 1000 pg/ml resulted in increased lytic reactivation in EBV latently
infected B95-8 cells (B). A similar pattern was observed when LCL2 was treated
with exogenous PGE2 (C).
J. Gandhi et al. / Virology 484 (2015) 1–14 9
prior blockage of EP receptors was necessary to block lytic reac-
tivation. It is possible that prior inhibition of EP receptors can
result in dysfunction of their downstream signaling important for
lytic reactivation of EBV. This clearly points to a speciﬁc role of
EP1/4 receptors and their downstream effectors in modulation of
EBV infection cycle. It is important to point out that Sodium
butyrate (NaB) which is a histone deacetylase inhibitor and TPA
which is a histone acetyltransferase inducer are known to activate
lytic viral replication in EBV latently infected cells (Daibata et al.,
1998; Luka et al., 1979). Sodium butyrate and TPA activates path-
ways that have been linked to EP receptors (Shelby et al., 2005).
Sodium butyrate activates the PKA (EP2 and EP4) pathway, while
TPA activates PKC (EP1) (Shelby et al., 2005). It has been previously
reported that EP receptors have distinct binding characteristics
and are coupled to different intracellular signaling pathways
resulting in the increase in levels of intracellular calcium (Reader
et al., 2011). The EP receptors have also been shown to be
functionally regulated epigenetically (Gray et al., 2009). The
intracellular PGE2 can also have pro-apoptotic affect in cancer
cells (Lalier et al., 2011). Therefore it is possible that COX-2/ PGE2
mediated lytic reactivation of EBV may also be using similar
pathways downstream of EP1 and EP4 receptors, and needs
further investigations.
It was earlier reported that patients suffering from chronic
inﬂammatory conditions characterized by upregulated COX-2
levels have high incidences of EBV associated malignancy (Kondo
et al., 2013; Lossius et al., 2013). Our data from co-cultivation
experiments demonstrate that upregulated COX-2 levels in
epithelial cells can induce lytic reactivation in co-cultured EBV
latently infected lymphoid cells. The addition of culture super-
natant from COX-2 expressing cells of epithelial origin or even
exogenous puriﬁed PGE2 was enough to trigger virus reactivation.
The reactivated virus was also fully functional and biologically
active as demonstrated by its transforming potential when
infected to fresh PBMCs. These observations now provide an
explanation for COX-2 to be a possible contributor to the inci-
dences of EBV associated cancers in people with chronic inﬂam-
matory conditions. It is possible that upregulated COX-2 levels in
such patients may affect latently infected EBV positive resting
B-cells at peripheral sites in the body by paracrine mode of action
via PGE2 (Fig. 8). Lytic reactivation in such patients will not only
allow the progeny virions to infect naïve cells but also increase the
probability of transformation of de novo infected cells. If such
patients are also immuno-compromised, the probability of trans-
formation and tumourigenesis will also be increased as is clinically
evident. This study now adds another dimension to our under-
standing of the role of inﬂammation in the progression of cancers
mediated by the oncogenic virus EBV.
Material and methods
Ethics statement
Blood samples for isolation of peripheral blood mononuclear
cells (PBMC) from healthy donors were collected after getting the
Fig. 7. EBV virions harvested from lytic reactivation by LPS induced EBV latently infected cells are biologically active. Human PBMCs infected with EBV harvested from LPS
induced B95-8 cells resulted in infection and transformation of B-cells. Uninfected PBMCs and PBMCs added with supernatant from uninduced B95-8 cells were used as a
negative control which did not show any aggregation, whereas PBMCs infected with EBV harvested from NaB/TPA induced B95-8 cells were used as positive controls to assay
the biological activity of EBV.
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protocol approval by the Institute Review Board of University of
Delhi South Campus. Every donor gave written and informed
consent and the samples were coded so as not to reveal any
personally identiﬁable information.
Constructs and cell lines
B95-8 (marmoset lymphoid cells) and LCL2 (lymphoblastoid
cell line) are latently infected with EBV (Shaw, Petit, and Leung,
1987). Akata cell line is of Burkitt's lymphoma origin and is
latently infected with EBV (Takada et al., 1991). Human Embryonic
Kidney HEK293, 293T and HeLa are EBV negative cell lines. B95-8
cells, LCL2 and Akata cells were maintained in RPMI-1640 (Lonza,
Basel, Switzerland, Cat no. 12-702F). HEK 293 and HEK 293T cells
were maintained in DMEM (Lonza, Basel, Switzerland, Cat no.
BE12-604F). The COX-2 expression plasmid was a gift from
Timothy Hla (Cornell University, Ithaca, NY).
Transfection
HEK293T cells were transfected by electroporation with a Bio-
Rad Gene Pulser electroporator. Ten million transfected cells were
plated in 100 mm dishes with 10 ml of growth medium and
incubated at 37 1C in 5% CO2. The cells were then harvested and
assayed for the experiment.
Real-time RT-PCR
Total RNA was collected from cells using TRI reagent (Sigma
Aldrich, St. Louis, MO, Cat. no. T9424) following the manufac-
turer's instructions. RNA was used to prepare cDNA using Super-
script ﬁrst strand reverse transcription kit (Life technologies,
Grand Island, NY, Cat. no. 11904-018) following manufacturer's
instructions. Speciﬁc primers were used to amplify 90–100 bp
regions of EP1, EP4 genes. GAPDH was used as an internal control
for normalization. The experiment was performed in triplicates.
For EP1, forward primer 50ATGGTGGGCCAGCTTGTC30 and reverse
primer 50GCCACCAACACCAGCATT30 were used. For EP4, forward
primer 50CGACCTTCTACA CGCTGGTATG30 and reverse primer
50CCGGGCTCACCAACAAAGT30 were used. For GAPDH, forward
primer 50 AAGGTGAAGGTCGGAGTCAACG 30 and reverse primer
50 CCTTCTCCATGGTGGTGAAGAC 30 were used.
EBV lytic reactivation and virus detection
Sodium butyrate (NaB), 12-tetra- decanoyl phorbol-13-acetate
(TPA) and Lipopolysaccharide (LPS) were used to induce lytic
reactivation of EBV in latently infected cells. TPA 1.6 mM (Sigma
Aldrich, St. Louis, MO, Cat. no. 79346), Sodium butyrate 2.5 mM
(Sigma Aldrich, St. Louis, MO, Cat. no. B588714) and LPS (Sigma
Aldrich, St. Louis, MO, Cat. no. L6143) was used at a concentration
of 1 μg/ml. The supernatant from induced cells was collected after
six days and centrifuged at 2000g for 5 min to remove any cellular
debris. It was then ﬁltered through 0.22u ﬁlter and was incubated
with 20 units of DNaseI (New England Biolabs, Ipswich, MA, Cat.
no. MO303L for 1 h at 37 1C to allow digestion of any virus free
DNA. The supernatant was then incubated for 10 min at 70 1C for
heat inactivation of DNaseI. The DNaseI treated supernatant was
then centrifuged at 200,000g for 1 h at 4 1C in ultra-centrifuge to
pellet the virus. The virus pellet was lysed with lysis buffer (3%
SDS, 75 mM Tris, 25 mM EDTA) and proteinase K. The viral DNA
was puriﬁed by phenol extraction and the presence of virus was
conﬁrmed by EBV-DNA speciﬁc real time PCR, targeting a 298 bp
sequence from the Bam-W fragment of the EBV genome using the
following primers: forward 50 CTTTAGAGGCGAATGGGCGC 30, and
reverse 50 AGGACCACTTTATACCAGGG 30. The Bam-W fragment
was ampliﬁed from viral DNA using Brilliant III Ultra-Fast SYBR
QPCR Master mix (Agilent Technologies, Santa Clara, CA), 1 mM of
Fig. 8. Schematic model shows that COX-2 upregulation in response to an inﬂammatory signal such as LPS results in EBV lytic reactivation from latently infected cells. The
upregulation of COX-2 is associated with EBV lytic cycle reactivation. Inhibition of COX-2 with speciﬁc inhibitor NS-398 blocks lytic reactivation. The up regulation of COX-2
enzyme results in increased production of the effector molecule PGE2 which has autocrine and paracrine action facilitated through EP1, EP2, EP3 and EP4 receptors. The EP1
and EP4 receptors are also upregulated in response to LPS induction and their inhibition directly reduces EBV lytic reactivation suggesting their possible involvement in
transition from the latent to lytic cycle in response to inﬂammatory signals. Also, PGE2 released from inﬂamed EBV negative epithelial cell can act via a paracrine mode of
action and lead to EBV lytic reactivation from latently infected cell.
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each primer and 1 μl of the viral DNA product in a total volume of
20 μl. Following cycling conditions were used in an 7900-HT Fast
Real Time PCR system (Applied Biosystem, Waltham, MA): 10 min
at 95 1C for initial denaturation, 40 cycles each at 15 s at 95 1C for
denaturation followed by 1 min at 60 1C for annealing and poly-
merization. Data were collected twice during every cycle after the
polymerization step and denaturation step. A melting curve
analysis was performed to verify the speciﬁcity of the products,
and the values for the relative quantitation were calculated by the
ΔΔCt method. The experiment was performed in triplicate.
Inhibitors
COX-2 speciﬁc inhibitor NS398 was used at a concentration of
50 μM (Sigma Aldrich, St. Louis, MO, Cat. no. N194). AH6808 is a
speciﬁc inhibitor of EP1/EP2 receptors, and was used at a con-
centration of 40 μM (Sigma Aldrich, St. Louis, MO, Cat. no. A1221).
The EP4 speciﬁc inhibitor AH23848 was used at concentration of
40 uM (Sigma Aldrich, St. Louis, MO, Cat. no. A8227).
PGE2 ELISA
In order to estimate the concentration of PGE2 in cell culture
supernatant, ELISA (Enzyme-linked immunosorbent assay) was
performed using Prostaglandin E2 EIA monoclonal kit (Cayman
Chemicals, Ann Arbor, MI, Cat no. 514010) following manufac-
turer's instructions. The ELISA was performed in triplicate, and the
results are presented as the means of standard errors of means
(SEMs).
Western blot
Prior to separation on SDS polyacrylamide gels, cell lysates
were mixed with 2x SDS loading buffer and heated to 95 1C for
5 min. Equal amounts of total protein was loaded in all wells. After
electrophoresis, the resolved proteins were transferred onto nitro-
cellulose membrane. The membranes were blocked in 5%
skimmed milk powder in PBS at room temperature for 30 min,
and then washed with TBST. The membranes were incubated with
primary antibody overnight at 4 1C. The membranes were washed
again and incubated with secondary antibody for 30 min at room
temperature. After washing, the membrane was scanned using
Typhoon scanner (GE Healthcare, Pittsburgh, PA). COX-2 was
detected in blots with anti-COX-2 mouse monoclonal antibody
(Cayman Chemicals, Ann Arbor, MI, Cat no. 160112) used at
dilution 1:1000, then probed with Alexa ﬂuor 488 goat anti-
mouse secondary antibody. COX-2 was detected as 72 KDa band
in western blots. For detection of the EP1 receptor we used anti-
EP1 rabbit polyclonal antibody (Cayman Chemicals, Ann Arbor, MI,
Cat no. 101740) at dilution 1:1000, which was probed with Alexa
ﬂuor goat anti-rabbit 488 secondary antibody (Life technologies,
Grand Island, NY, Cat. no. 11034). EP1 was detected at 42 KDa. For
EP4 we used anti-EP4 rabbit polyclonal antibody (Cayman Chemi-
cals, Ann Arbor, MI, Cat no. 101775) at dilution 1:1000. It was
probed with Alexa ﬂuor goat anti-rabbit secondary antibody (Life
technologies, Grand Island, NY, Cat. no. A11034). For detection of
EBV glycoprotein gp350, anti-gp350 mouse monoclonal antibody
(Santa Cruz, Dallas, TX, Cat. no. SC57724) was used at a dilution of
1:500. It was probed with Alexa ﬂuor goat anti-mouse secondary
antibody. EBV glycoprotein gp350 was detected at 113 KDa.
GAPDH was used as internal loading control.
Immunoﬂuorescence
Induced and control cells were grown on poly-L-lysine coated
coverslips. Cells were washed with 1x PBS and ﬁxed with acetone:
methanol (1:1) at 201C for 20 min followed by washing with 1x
PBS. The cells were permeabilized using 0.5% Triton X 100 (Sigma
Aldrich, St. Louis, MO, Cat. no. T8787) and blocked with cold ﬁsh
gelatin (1% BSA, 1% cold ﬁsh skin gelatin, 0.5% Triton X-100, 0.01%
PBS pH 7.2–7.4) for 30 min at room temperature. This was
followed by incubation with primary antibody (described in
Western blot section) overnight at 4 1C. After three washings with
PBS, cells were incubated with secondary antibody for 30 min
followed by DAPI to stain the nuclei of the cells. The cover slips
were mounted using ﬂuoromount (90% glycerol and 0.1% p-
phenylenediamine in PBS pH 9.0). The presence of the protein of
interest was detected by confocal microscopy and signal intensity
was quantitated using Image J software (Schneider et al., 2012).
Co-cultivation of COX-2 expressing adherent cells with EBV latently
infected cells
Ten million 293T cells were grown in 100 mm cell culture dish
and incubated with LPS (1 μg/ml) to induce COX-2 expression. The
media was replaced with fresh media after 6 h after washing the
cells with DPBS to remove any traces of LPS. These COX-2
expressing cells were then co-cultivated with 10 million EBV
infected LCLs. Both the cells were co-cultivated by incubating for
6 days after which the culture supernatant was collected and
processed for detection and presence of EBV as described earlier.
Supernatant from uninduced 293T cells co-cultivated with LCLs
was used as a control. The 293T cells transfected with COX-2
expression plasmid or cell culture supernatant alone from such
cells were also used for co-cultivation with LCLs. Mock transfected
293T cells or cell culture supernatant from mock transfected cells
were used as controls.
Infection of PBMC with EBV particles
EBV was re-activated from the EBV positive cell line B95-8
using LPS (1 μg/ml). Exponentially growing B95-8 cells were
induced with LPS for 24 h. Then cells were washed with phosphate
buffer saline (PBS) three times to remove any residual LPS, re-
suspended in 10% RPMI and incubated for 4 days. The cells were
then centrifuged at 1000g to pellet them and the culture super-
natant was collected. The supernatant was ﬁltered through a
0.22 μm ﬁlter and stored at 80 1C until used. To conﬁrm the
presence of EBV, we processed 1 ml of culture supernatant for viral
DNA extraction followed by real time PCR ampliﬁcation to detect
the BamW fragment of EBV as described earlier. For Peripheral
blood mononuclear cells (PBMC) isolation, blood was collected
from volunteers after obtaining informed consent from them.
Eight ml of blood was drawn using BD safety-lok blood collection
set (BD Biosciences, San Hose, CA, Cat. no. 367283) in BD
vacutainer CPT cell preparation tube with sodium heparin (BD
Biosciences, San Hose, CA, Cat. no. 362753). The BD vacutainer
with blood was centrifuged at 1500g for 15 min at room tempera-
ture. After centrifugation, mononuclear cells and platelets sepa-
rated in whitish layer of buffy coat under plasma layer. The
mononuclear cells were collected and washed with PBS, then re-
suspended in 20% RPMI at concentration of 1106 cells/ml.
Cyclosporine A (Sigma Aldrich, St. Louis, MO, Cat. no. C3662) was
added at 2 μg/ml concentration to prevent activation of T cells. To
test the biological activity of virus reactivated in response to COX-2
expression, the culture supernatant from uninduced B95-8 cells or
from LPS induced B95-8 cells prepared previously was added to an
equal volume of mononuclear cells and incubated at 37 1C. The
cells were observed daily until aggregates of cells started appear-
ing indicating infection and transformation of infected B cells.
After 2–3 days post-infection, clusters of cells were visible by light
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microscopy. Fresh media was added subsequently to the culture as
needed.
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